HRT Financial LP trims Shuttle (SHPH) stake with early July share sales

Rhea-AI Filing Summary

HRT Financial LP, a ten percent owner of Shuttle Pharmaceuticals Holdings, Inc., reported selling a total of 29,111 shares of common stock in early July. It sold 18,531 shares on July 8 at $3.52 per share and 10,580 shares on July 7 at $3.33 per share in open-market transactions.

After these sales, HRT Financial LP directly holds 52,274 shares of Shuttle Pharmaceuticals common stock. The filing shows straightforward open-market sales with no derivative exercises or related derivative positions reported.

Insider Trade Summary

Net Seller: 29,111 shares ($100,461)

Net Sell 2 txns

Insider HRT FINANCIAL LP

Role null

Sold 29,111 shs ($100K)

Type	Security	Shares	Price	Value
Sale	Common Stock	18,531	$3.52	$65K
Sale	Common Stock	10,580	$3.33	$35K

Holdings After Transaction: Common Stock — 52,274 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold July 8, 2026: 18,531 shares Shares sold July 7, 2026: 10,580 shares Total shares sold: 29,111 shares +3 more

6 metrics

Shares sold July 8, 2026 18,531 shares Open-market sale of common stock at $3.52 per share

Shares sold July 7, 2026 10,580 shares Open-market sale of common stock at $3.33 per share

Total shares sold 29,111 shares Combined open-market sales reported in this Form 4

Price per share July 8 sale $3.52/share Common stock sale on July 8, 2026

Price per share July 7 sale $3.33/share Common stock sale on July 7, 2026

Shares held after transactions 52,274 shares Direct SHPH common stock holdings following the latest sale

Key Terms

open-market sale, ten percent owner, non-derivative, Form 4

4 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

ten percent owner regulatory

"HRT FINANCIAL LP is marked as a ten percent owner"

non-derivative financial

"transaction_type is listed as "non-derivative" for each trade"

Form 4 regulatory

"Insider activity is reported on SEC Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/09/2026 - 05:50 PM Accepted by SEC EDGAR 07/09/2026 - 05:50 PM Learn about SEC filing dates

FAQ

What did HRT Financial LP report in this Form 4 for SHPH?

HRT Financial LP reported selling shares of Shuttle Pharmaceuticals (SHPH) common stock. The Form 4 shows two open-market sales on July 7 and July 8, 2026, and updates the firm’s remaining direct holdings after these transactions.

How many Shuttle Pharmaceuticals (SHPH) shares did HRT Financial LP sell?

HRT Financial LP sold a total of 29,111 SHPH shares. This consisted of 10,580 shares sold on July 7, 2026, and 18,531 shares sold on July 8, 2026, all reported as open-market sales of common stock.

At what prices did HRT Financial LP sell SHPH shares?

HRT Financial LP sold SHPH common stock at $3.33 and $3.52 per share. The filing reports 10,580 shares sold at $3.33 on July 7, 2026, and 18,531 shares sold at $3.52 on July 8, 2026, in open-market transactions.

How many SHPH shares does HRT Financial LP hold after these sales?

After the reported sales, HRT Financial LP directly holds 52,274 shares of Shuttle Pharmaceuticals common stock. This post-transaction holding is disclosed in the Form 4 as the total number of shares beneficially owned following the latest transaction.

Were any derivative securities involved in HRT Financial LP’s SHPH transactions?

No derivative securities were reported in this Form 4. All transactions involved non-derivative common stock, and the derivativeSummary section shows no remaining options, warrants, or other derivative positions related to Shuttle Pharmaceuticals common stock.

What type of transactions did HRT Financial LP execute in SHPH stock?

HRT Financial LP executed open-market sales of Shuttle Pharmaceuticals common stock. Both transactions are coded “S” and described as sales in open market or private transactions, indicating straightforward dispositions rather than option exercises or tax-related transfers.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HRT FINANCIAL LP

(Last) (First) (Middle)

3 WORLD TRADE CENTER, 175 GREENWICH STRE

76TH FLOOR

(Street)

NEW YORK NEW YORK 10007

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/07/2026		S		10,580	D	$3.33	70,805	D
Common Stock	07/08/2026		S		18,531	D	$3.52	52,274	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Adam Nunes	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)